According to DelveInsight's estimates, the increasing
prevalence of diabetes, obesity, hormonal disorders, socioeconomic
factors, changes in sedentary lifestyle, and growing consumption of
unhealthy diets among women, is expected to fuel the polycystic
ovary syndrome market.
LAS
VEGAS, June 20, 2024 /PRNewswire/ --
DelveInsight's Polycystic Ovarian Syndrome Market
Insights report includes a comprehensive understanding of
current treatment practices, polycystic ovarian syndrome emerging
drugs, market share of individual therapies, and current and
forecasted market size from 2020 to 2034, segmented into 7MM
[the United States, the EU4
(Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Polycystic Ovarian Syndrome Market
Report
- According to DelveInsight's analysis, the market size for
polycystic ovarian syndrome is expected to grow significantly
by 2034.
- According to the data provided by the Centers for Disease
Control and Prevention (CDC), PCOS is one of the most common causes
of female infertility, affecting 6% to 12% of US women of
reproductive age.
- According to the data published by NHS, PCOS is thought to be
very common, affecting about 1 in every 10 women in the
UK.
- Leading polycystic ovarian syndrome companies such as
Spruce Biosciences, and others are developing novel
polycystic ovarian syndrome drugs that can be available in the
polycystic ovarian syndrome market in the coming years.
- The promising polycystic ovarian syndrome therapies in the
pipeline include Tildacerfont, among others.
Discover which therapies are expected to grab the major
polycystic ovarian syndrome market share @ Polycystic
Ovarian Syndrome Market Report
Polycystic Ovarian Syndrome Overview
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine
disorder in women, presenting a variety of signs, symptoms, and
phenotypes. These can include reproductive, endocrine, and
metabolic changes. PCOS is marked by dysfunction of the
hypothalamic–pituitary–ovary axis and anovulation. Unlike other
ovulatory failures characterized by inadequate ovarian follicle
growth or suppressed gonadotropin secretion, PCOS usually involves
androgen excess and subtle changes in serum levels of gonadotropins
and estrogens that routine tests may not detect.
The exact cause of PCOS remains unclear, but many women with the
condition exhibit insulin resistance. Elevated insulin levels can
lead to increased androgen production. Obesity can also raise
insulin levels, exacerbating PCOS symptoms. PCOS often runs in
families. Symptoms of PCOS may include missed or irregular periods,
very light periods, enlarged ovaries or those with many cysts,
excessive body hair (hirsutism) on the chest, stomach, and back,
weight gain, particularly around the abdomen, acne or oily skin,
and infertility.
Polycystic Ovarian Syndrome Epidemiology Segmentation
The polycystic ovarian syndrome epidemiology section provides
insights into the historical and current polycystic ovarian
syndrome patient pool and forecasted trends for the 7MM. It helps
recognize the causes of current and forecasted patient trends by
exploring numerous studies and views of key opinion leaders.
The polycystic ovarian syndrome market report proffers
epidemiological analysis for the study period 2020–2034 in the 7MM
segmented into:
- Total Prevalent Cases of Polycystic Ovarian Syndrome
- Diagnosed Prevalent cases of Polycystic Ovarian Syndrome
- Treatable Cases of Polycystic Ovarian Syndrome
Polycystic Ovarian Syndrome Treatment Market
The primary goal of treating polycystic ovarian syndrome is to
manage symptoms and lower the risk of long-term complications.
Presently, most treatments target the patient's main concern. The
focus of treatment is on alleviating symptoms of hyperandrogenism,
regulating menstrual cycles, and facilitating conception.
Maintaining a healthy weight by following a balanced diet and
engaging in regular exercise can enhance insulin sensitivity and
help regulate menstrual cycles in individuals with PCOS who are
overweight or obese. Incorporating complex carbohydrates, lean
proteins, and plenty of vegetables into the diet can be
advantageous. Some women with PCOS might find a low-carbohydrate or
low-glycemic index diet particularly beneficial. Physical activity
also aids in improving insulin resistance and managing weight.
Spironolactone and flutamide can help decrease
excess hair growth and acne by inhibiting the effects of male
hormones (androgens). While Metformin is not approved for
PCOS treatment in the UK, it can be prescribed "off-label" due to
its benefits for many women with PCOS who have insulin resistance.
Metformin can aid in improving fertility, regulating menstrual
cycles, and lowering miscarriage risks. Additionally, it offers
long-term health benefits like reducing high cholesterol levels and
decreasing the risk of heart disease.
To know more about polycystic ovarian syndrome treatment
guidelines, visit @ Polycystic Ovarian Syndrome
Management
Polycystic Ovarian Syndrome Pipeline Therapies and Key
Companies
The pipeline for PCOS is bleak with only a few companies working
diligently. Of all the major market players, Spruce
Biosciences is developing Tildacerfont. Tildacerfont is
a CRF1 receptor antagonist developed to potentially provide
significantly better disease management and reduce steroid use in
patients with classic congenital adrenal hyperplasia and other
conditions with elevated adrenocorticotropic hormone (ACTH) levels.
It works by binding to CRF1 receptors in the pituitary gland,
thereby inhibiting the overproduction of ACTH and reducing the
production of adrenal androgens like androstenedione, a precursor
to testosterone. Tildacerfont is typically well-tolerated in both
healthy individuals and those with rare endocrine disorders.
Spruce is carrying out the P.O.W.E.R. study, a randomized,
placebo-controlled, dose-escalation trial to assess the safety and
efficacy of tildacerfont titrated to 200 mg once daily compared to
a placebo over 12 weeks in subjects with PCOS and elevated adrenal
androgens, measured by baseline dehydroepiandrosterone sulfate
(DHEAS) levels. PCOS is a common hormonal disorder in women of
reproductive age, characterized by hirsutism, irregular menstrual
cycles, infertility, and ovarian cysts.
If approved, Tildacerfont could be beneficial for women with a
rare form of PCOS resulting from hyperresponsiveness to adrenal
androgens.
Discover more about polycystic ovarian syndrome drugs in
development @ Polycystic Ovarian Syndrome Clinical
Trials
Polycystic Ovarian Syndrome Market Dynamics
The dynamics of the polycystic ovarian syndrome market are
expected to change in the coming years. Rising awareness
about PCOS and its associated complications, such as infertility,
metabolic syndrome, and diabetes, has heightened the demand for
effective diagnostic and treatment options. Advances in
medical technology and diagnostics have also played a
significant role, with improved imaging techniques and blood tests
enabling earlier and more accurate detection of PCOS. Additionally,
the growing emphasis on personalized medicine and tailored
treatment regimens is fueling the market, as healthcare
providers seek to offer more specific and effective therapies for
managing PCOS symptoms.
Furthermore, potential therapies are being investigated for the
treatment of polycystic ovarian syndrome, and it is safe to predict
that the treatment space will significantly impact the polycystic
ovarian syndrome market during the forecast period. Moreover,
the anticipated introduction of emerging therapies with
improved efficacy and a further improvement in the diagnosis
rate are expected to drive the growth of the polycystic ovarian
syndrome market in the 7MM.
However several factors may impede the growth of the polycystic
ovarian syndrome market. One of the major challenges is the lack
of standardized diagnostic criteria, which can lead to
underdiagnosis or misdiagnosis, thus limiting the potential market
size. Treatment adherence is another concern, as the chronic
nature of PCOS often requires long-term management strategies that
patients may find difficult to maintain. Furthermore, there is a
need for more comprehensive and effective treatment options;
current therapies primarily focus on symptom management rather than
addressing the underlying causes of PCOS.
Moreover, polycystic ovarian syndrome treatment poses a
significant economic burden and disrupts patients' overall
well-being and QOL. Furthermore, the polycystic ovarian
syndrome market growth may be offset by failures and
discontinuation of emerging therapies, unaffordable
pricing, market access and reimbursement issues, and a
shortage of healthcare specialists. In addition, the
undiagnosed, unreported cases and the unawareness about the
disease may also impact the polycystic ovarian syndrome market
growth.
Polycystic Ovarian
Syndrome Market Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
Key Polycystic Ovarian
Syndrome Companies
|
Spruce
Biosciences, and others
|
Key Pipeline Polycystic Ovarian Syndrome
Therapies
|
Tildacerfont, and
others
|
Scope of the Polycystic Ovarian
Syndrome Market Report
- Therapeutic Assessment: Polycystic Ovarian
Syndrome current marketed and emerging therapies
- Polycystic Ovarian Syndrome Market
Dynamics: Key Market Forecast Assumptions of Emerging
Polycystic Ovarian Syndrome Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Polycystic
Ovarian Syndrome Market Access and Reimbursement
Download the report to understand which factors are driving
polycystic ovarian syndrome market trends @ Polycystic
Ovarian Syndrome Market Trends
Table of Contents
1.
|
Polycystic Ovarian
Syndrome Key Insights
|
2.
|
Polycystic Ovarian
Syndrome Report
Introduction
|
3.
|
Polycystic Ovarian
Syndrome Overview at a Glance
|
4.
|
Polycystic Ovarian
Syndrome Executive
Summary
|
5
|
Polycystic Ovarian
Syndrome Key Events
|
6
|
Epidemiology and Market
Forecast Methodology
|
6.
|
Disease Background and
Overview
|
7.
|
Polycystic Ovarian
Syndrome Treatment and
Management
|
8.
|
Polycystic Ovarian
Syndrome Guidelines
|
9.
|
Polycystic Ovarian
Syndrome Epidemiology and Patient
Population
|
10.
|
Patient
Journey
|
11.
|
Key Endpoints in
Polycystic Ovarian Syndrome
|
12.
|
Polycystic Ovarian
Syndrome Marketed Drugs
|
13.
|
Polycystic Ovarian
Syndrome Emerging Drugs
|
14.
|
7MM Polycystic Ovarian Syndrome Market Analysis
|
15.
|
Market Access and
Reimbursement
|
16.
|
KOL Views
|
17.
|
Unmet Needs
|
18.
|
SWOT
Analysis
|
19.
|
Appendix
|
20.
|
DelveInsight
Capabilities
|
21.
|
Disclaimer
|
22.
|
About
DelveInsight
|
Related Reports
Polycystic Ovarian Syndrome Pipeline
Polycystic Ovarian Syndrome Pipeline Insight –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key polycystic ovarian
syndrome companies, including Spruce Biosciences, Zydus
Therapeutics, AbbVie, among others.
Polycystic Ovarian Syndrome Epidemiology Forecast
Polycystic Ovarian Syndrome Epidemiology Forecast –
2032 report delivers an in-depth understanding of the
disease, historical and forecasted polycystic ovarian syndrome
epidemiology in the 7MM, i.e., the United
States, EU5 (Germany,
Spain, Italy, France, and the United Kingdom), and Japan.
Type 2 Diabetes Pipeline
Type 2 Diabetes Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key type 2 diabetes companies,
including Sanofi, Eli Lilly and Company, Novartis, among
others.
Type 2 Diabetes Market
Type 2 Diabetes Market Insights, Epidemiology, and Market
Forecast – 2032 report delivers an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key type 2 diabetes companies, including Eli Lilly
and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene,
Pfizer, Sciwind Biosciences USA
Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma
Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc.,
Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc.,
Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics,
Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/polycystic-ovarian-syndrome-market-to-advance-at-moderate-cagr-during-the-study-period-20202034--delveinsight-302177654.html
SOURCE DelveInsight Business Research, LLP